Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
38 hedge funds and large institutions have $128M invested in Sinovac Biotech, Ltd in 2016 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 5 closing their positions.
91% more capital invested
Capital invested by funds: $66.9M → $128M (+$61.2M)
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
6% more funds holding
Funds holding: 36 → 38 (+2)
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $30K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$882K |
| 2 |
Renaissance Technologies
New York
|
+$300K |
| 3 |
SIM
Spark Investment Management
New York
|
+$202K |
| 4 |
Two Sigma Investments
New York
|
+$149K |
| 5 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
+$115K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$1.21M |
| 2 |
Citigroup
New York
|
-$647K |
| 3 |
PRCM
Pine River Capital Management
Minnetonka,
Minnesota
|
-$627K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$388K |
| 5 |
FIM
Freedom Investment Management
Hartford,
Connecticut
|
-$281K |
SVA Hedge Fund Activity: Q4 2016 in Review
38 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q4 2016, worth a combined $128M — up 91% from $66.9M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new SVA positions and 5 closed out — a net gain of 3 holders — while 8 added to existing stakes and 11 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $882K. The largest seller was Acuta Capital Partners, exiting entirely with an estimated $1.21M sold.
- 38 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q4 2016, up from 36 in Q3 2016.
- Funds reported $128M of Sinovac Biotech, Ltd stock for Q4 2016, up 91% quarter-over-quarter.
- 8 funds opened new Sinovac Biotech, Ltd positions in Q4 2016 and 5 closed out, a net change of +3 holders.
- The largest Sinovac Biotech, Ltd buyer in Q4 2016 was Wellington Management Group, an estimated $882K added.
- The largest Sinovac Biotech, Ltd seller in Q4 2016 was Acuta Capital Partners, an estimated $1.21M sold.
Based on aggregated 13F filings for Q4 2016.